Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Dova Pharmaceuticals, Inc. (DOVA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/29/2019 |
GN
| SHAREHOLDER ALERT: WeissLaw LLP Reminds DOVA, TRCB, EEI, and UCFC Shareholders About Its Ongoing Investigations |
| 10/02/2019 |
GN
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Dova Pharmaceuticals, Inc. to Swedish Orphan Biovitrum AB is Fair to Shareholders |
| 09/30/2019 |
GN
| Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi) |
| 09/25/2019 |
GN
| Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference |
| 09/03/2019 |
GN
| Dova Pharmaceuticals to Present at Upcoming Investor Conferences |
| 07/30/2019 |
GN
| Dova Pharmaceuticals to Announce Second Quarter 2019 Financial Results on August 6, 2019 |
| 07/19/2019 |
GN
| Dova Pharmaceuticals Announces DOPTELET® (avatrombopag) Now Commercially Available in the United States for Treatment of Chronic Immune Thrombocytopenia (ITP) |
| 06/27/2019 |
GN
| Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP) |
| 06/24/2019 |
GN
| Dova Pharmaceuticals Announces Four Presentations on Avatrombopag in Patients with Chronic Immune Thrombocytopenia at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress |
| 05/20/2019 |
GN
| Dova Pharmaceuticals to Present at the UBS Global Healthcare Conference |
| 04/30/2019 |
GN
| Dova Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 7, 2019 |
| 04/29/2019 |
GN
| Dova Pharmaceuticals Receives Positive Opinion from CHMP for DOPTELET® (avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease |
| 04/02/2019 |
GN
| Dova Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference |
| 03/05/2019 |
GN
| Dova Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference |
| 02/19/2019 |
GN
| Dova Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019 |
| 01/02/2019 |
GN
| Dova Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference |
| 12/20/2018 |
GN
| Dova Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 11/05/2018 |
GN
| Dova Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for DOPTELET® (avatrombopag) for the Treatment of Chronic Immune Thrombocytopenia (ITP) |
| 10/16/2018 |
GN
| Analysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis Pharmaceuticals, and Minerva Neurosciences — Research Highlights Growth, Revenue, and Consolidated Results |
| 09/26/2018 |
GN
| Dova Pharmaceuticals to Present at Upcoming Investor Conferences |
| 09/11/2018 |
GN
| Dova Pharmaceuticals to Host Investor & Analyst Day on September 20, 2018 |
| 09/04/2018 |
GN
| Dova Pharmaceuticals Submits Supplemental New Drug Application for DOPTELET® (avatrombopag) for the Treatment of Chronic ITP |
| 08/16/2018 |
GN
| Analysis: Positioning to Benefit within Amtech, NL Industries, Dova Pharmaceuticals, Sientra, Dorian LPG, and Assembly Biosciences — Research Highlights Growth, Revenue, and Consolidated Results |
| 08/09/2018 |
GN
| Dova Pharmaceuticals Reports Second Quarter 2018 Operating and Financial Results |
| 07/26/2018 |
GN
| Dova Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 9, 2018 |
| 06/25/2018 |
GN
| Nancy J. Wysenski Joins Dova Pharmaceuticals' Board of Directors |
| 05/31/2018 |
GN
| Dova Pharmaceuticals Announces Availability of DOPTELET® in the United States |
| 05/29/2018 |
GN
| Dova Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference |
| 05/25/2018 |
GN
| Market Trends Toward New Normal in inTest, Westamerica, Simmons First National, Dova Pharmaceuticals, ScanSource, and Horizon Bancorp (IN) — Emerging Consolidated Expectations, Analyst Ratings |
| 05/21/2018 |
GN
| Dova Pharmaceuticals Announces U.S. FDA Approval of DOPTELET® (avatrombopag) |
| 05/09/2018 |
GN
| Dova Pharmaceuticals Reports First Quarter 2018 Operating and Financial Results |
| 05/02/2018 |
GN
| Dova Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 9, 2018 |
| 04/03/2018 |
GN
| Investor Expectations to Drive Momentum within Horizon Bancorp (IN), Allegiant Travel, Littelfuse, Dova Pharmaceuticals, BOK Financial, and Northfield — Discovering Underlying Factors of Influence |
| 02/22/2018 |
GN
| Dova Pharmaceuticals, Inc. Announces Pricing of Offering of Common Stock |
|
|
|